Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
Launched by MASSACHUSETTS GENERAL HOSPITAL · Mar 10, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new digital program designed to help people who are dealing with both depression and cannabis use issues. The goal is to see if this program, called Amplification of Positivity - Cannabis Use (AMP-C), is easy to use, acceptable to participants, and effective in improving mood and reducing cannabis use. Participants will be randomly assigned to either use this program or track their symptoms, and researchers will look at how well they stick with the program, their feelings of happiness, and changes in their cannabis use and depression symptoms.
To be eligible for this study, participants need to be at least 18 years old, live in the United States, and be able to read and understand English. They should also be experiencing moderate symptoms of depression and have issues with cannabis use. Importantly, they must be interested in getting help for these problems. However, individuals with certain mental health conditions like severe mood disorders or those currently in therapy will not be part of this trial. The study is not yet recruiting, but if you or someone you know fits the criteria, it could be a valuable opportunity to receive support and contribute to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥ 18 years
- • Resides in the United States
- • Able to read and understand English and willing to provide informed consent/comply with the study protocol
- • Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
- • Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
- • Current elevated anhedonia, as indicated by the PHQ-9
- • Interest in receiving treatment for their cannabis use and/or depression
- • Meet criteria for current MDD and CUD per the DSM-5
- Exclusion Criteria:
- • History of a psychotic disorder or bipolar disorder type I/II
- • Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
- • Current psychotherapy engagement
- • Changes in psychotropic medication within six weeks of the start of study
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported